Home › NDC Lookup › RxCUI directory › RxCUI 995156

Lacosamide 10 MG/ML Oral Solution [Vimpat] — RxCUI 995156

RxNorm drug concept · Semantic branded drug
RxCUI 995156 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 14 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI995156
Official nameLacosamide 10 MG/ML Oral Solution [Vimpat]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVimpat 10 MG/ML Oral Solution; VIMPAT 10 MG in 1 mL Oral Solution; Vimpat 10 MG per 1 ML Oral Solution
FDA products mapped6
Package NDCs mapped14
Reported Medicaid activity (SDUD)34,588 prescriptions · 42 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lacosamide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats partial-onset seizures, and it is also used as add-on treatment for primary generalized tonic-clonic seizures. Which age groups it covers depends on the product, so your...
  • Tablets and oral solution are usually taken twice a day, with or without food. Motpoly XR is a once-daily capsule that you swallow whole, without opening, chewing or crushing. Foll...
  • Dizziness is the big one, along with headache, double or blurry vision, nausea, sleepiness and balance trouble. These are most noticeable when starting or raising the dose. Tell yo...
  • Call right away for fainting, a very slow or irregular heartbeat, or new or worsening depression or suicidal thoughts. Also call for fever with rash or swelling, which can be a ser...
📖 Read our full Lacosamide guide →

🕸️ Concept Web — How Lacosamide 10 MG/ML Oral Solution [Vimpat] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lacosamide 10 MG/ML Oral Solution [Vimpat] RxCUI 995156

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lacosamide 623400
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vimpat 809979
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lacosamide Oral Solution 993855
    • Lacosamide Oral Liquid Product 1162528
    • Lacosamide Oral Product 1162529
    • Lacosamide Oral Solution [Vimpat] 995155
    • Vimpat Oral Liquid Product 1186609
    • Vimpat Oral Product 1186610
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lacosamide 10 MG/ML Oral Solution SCD · 993856
  • Lacosamide 10 MG/ML SCDC · 809972
  • Lacosamide Oral Solution SCDF · 993855
  • Lacosamide Oral Liquid Product SCDG · 1162528
  • Lacosamide Oral Product SCDG · 1162529

Brand-Name Concepts

  • Lacosamide 10 MG/ML [Vimpat] SBDC · 809983
  • Lacosamide Oral Solution [Vimpat] SBDF · 995155
  • Vimpat Oral Liquid Product SBDG · 1186609
  • Vimpat Oral Product SBDG · 1186610
  • Vimpat BN · 809979

📦 FDA Products & Package NDCs

6 products · 14 package NDCs
14 package NDCs map to RxCUI 995156 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00131-1810-67 10 VIAL, GLASS in 1 CARTON (0131-1810-67) / 20 mL in 1 VIAL... Vimpat UCB, Inc. 2009-05-26
00131-2477-35 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0131-2477-35) Vimpat UCB, Inc. 2009-05-26
00131-2477-60 6 BLISTER PACK in 1 CARTON (0131-2477-60) / 10 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-2477-99 1 BLISTER PACK in 1 CARTON (0131-2477-99) / 14 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-2478-35 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0131-2478-35) Vimpat UCB, Inc. 2009-05-26
00131-2478-60 6 BLISTER PACK in 1 CARTON (0131-2478-60) / 10 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-2478-99 1 BLISTER PACK in 1 CARTON (0131-2478-99) / 14 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-2479-35 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0131-2479-35) Vimpat UCB, Inc. 2009-05-26
00131-2479-60 6 BLISTER PACK in 1 CARTON (0131-2479-60) / 10 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-2479-99 1 BLISTER PACK in 1 CARTON (0131-2479-99) / 14 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-2480-35 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0131-2480-35) Vimpat UCB, Inc. 2009-05-26
00131-2480-60 6 BLISTER PACK in 1 CARTON (0131-2480-60) / 10 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-2480-99 1 BLISTER PACK in 1 CARTON (0131-2480-99) / 14 TABLET, FILM... Vimpat UCB, Inc. 2009-05-26
00131-5410-72 200 mL in 1 BOTTLE, GLASS (0131-5410-72) Vimpat UCB, Inc. 2010-04-20
Observed labelers: UCB, Inc. (14) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.